{"id":"nicofuranose","rwe":[],"tags":[{"label":"nicofuranose","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C10AD03","category":"atc"},{"label":"Active","category":"status"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"bradilan","offLabel":[],"synonyms":["nicofuranose","bradilan","L-Nicofuranosum","nicofurazone"],"timeline":[],"approvals":[],"brandName":"Bradilan","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"nicofuranose","explanation":"Imagine your cells have locks on them, and Bradilan has a key that fits into those locks. When it binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as reducing inflammation or improving cellular function. However, the exact details of how Bradilan interacts with its target are still not well understood.","oneSentence":"Bradilan works by interacting with a specific cellular target to produce a therapeutic effect.","technicalDetail":"Bradilan's mechanism of action is thought to involve the inhibition of a specific enzyme or protein, although the precise molecular details are currently unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1916","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NICOFURANOSE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:56:48.582187","biosimilars":[],"competitors":[{"drugName":"nicotinic acid","drugSlug":"nicotinic-acid","fdaApproval":"1957-07-24","relationship":"same-class"}],"genericName":"nicofuranose","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nicotinic-acid","brandName":"nicotinic acid","genericName":"nicotinic acid","approvalYear":"1957","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"2275","NDDF":"001052","UNII":"GF99P6327K","CHEBI":"CHEBI:135846","VANDF":"4017661","INN_ID":"1565","RXNORM":"104486","UMLSCUI":"C0354652","ChEMBL_ID":"CHEMBL1697844","KEGG_DRUG":"D07189","DRUGBANK_ID":"DB13422","PDB_CHEM_ID":" NIO","PUBCHEM_CID":"25495","SNOMEDCT_US":"273943001","MESH_SUPPLEMENTAL_RECORD_UI":"C100123"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C10AD03","allCodes":["C10AD03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bradilan, also known as Nicofuranose, is a small molecule drug in the nicofuranose class. Its exact target and mechanism of action are unknown, but it is being developed for potential therapeutic applications. The commercial status of Bradilan is unclear, and it is not yet FDA-approved for any indications. Further research is needed to determine its efficacy and safety profile. As a result, key safety considerations and potential side effects are currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}